|Day Low/High||0.25 / 1.00|
|52 Wk Low/High||0.05 / 110.00|
It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.